Entity

Time filter

Source Type

Songgang-dong, South Korea

Patent
Yungjin Pharmaceutical Co. and Jeonnam Bioindustry Foundation | Date: 2014-04-29

The present invention relates to a composition for promoting osteoblast or cartilage cell differentiation. More particularly, the present invention relates to a composition, which includes stauntonia hexaphylla leaf extract that may be safely used without toxicity and side effects by using a natural ingredient, for promoting bone (tissue) formation to be used for suppressing and treating bone and cartilage tissue damage. A pharmaceutical composition including the stauntonia hexaphylla leaf extract according to the present invention as an active ingredient may be used as a medicine for periodontitis or osteoporosis to treat or prevent periodontitis or osteoporosis.


Im Y.-J.,Chonbuk National University | Jeon J.-Y.,Chonbuk National University | Kim E.-Y.,Chonbuk National University | Kim Y.,Chonbuk National University | And 5 more authors.
Clinical Therapeutics | Year: 2015

Purpose To provide consistent pain relief and improve convenient sustained release (SR), a fixed-dose combination tramadol/acetaminophen tablet was formulated. This study aimed to evaluate the pharmacokinetic profiles of an SR 75-mg tramadol/650-mg acetaminophen formulation after a single dose compared with an immediate release (IR) 37.5-mg tramadol/325-mg acetaminophen formulation after 2 doses and at steady state and to assess the effect of food on the pharmacokinetic SR formulation profile after a single dose. Methods Two clinical trials were conducted: (1) an open-label, randomized, 3-period, 3-treatment, crossover study to assess the pharmacokinetic SR (one 75-mg tramadol/650-mg acetaminophen combination tablet) formulation profiles after a single dose and IR (one 37.5-mg tramadol/325-mg acetaminophen combination tablet q6h for 2 doses) formulation profiles after 2 doses and the effect of food intake on healthy male subjects and (2) an open, randomized, 2-period, 2-treatment multiple dose crossover study to evaluate the steady-state pharmacokinetic SR and IR formulation profiles. Safety assessments were performed. Findings Forty-three subjects completed each study protocol. The SR combination tramadol/acetaminophen formulation was clinically and statistically equivalent to the IR combination formulation in the fasting state. When tramadol and acetaminophen tablets were administered with food, the time to peak plasma concentrations and the tramadol/acetaminophen absorption were unaffected. There was no serious adverse event reported. Implications The SR combination tramadol/acetaminophen tablet exhibited similar exposure and absorption rates compared with those of the IR formulation of tramadol, O-desmethyltramadol, and acetaminophen. The SR formulation may be more convenient for patients and has the potential to enhance compliance and pain control. ClinicalTrials.gov identifier: NCT01880125 © 2015 Elsevier HS Journals, Inc. Source


Im Y.-J.,Chonbuk National University | Jeon J.-Y.,Chonbuk National University | Kim E.-Y.,Chonbuk National University | Kim Y.,Chonbuk National University | And 5 more authors.
Clinical Therapeutics | Year: 2015

Purpose: To provide consistent pain relief and improve convenient sustained release (SR), a fixed-dose combination tramadol/acetaminophen tablet was formulated. This study aimed to evaluate the pharmacokinetic profiles of an SR 75-mg tramadol/650-mg acetaminophen formulation after a single dose compared with an immediate release (IR) 37.5-mg tramadol/325-mg acetaminophen formulation after 2 doses and at steady state and to assess the effect of food on the pharmacokinetic SR formulation profile after a single dose. Methods: Two clinical trials were conducted: (1) an open-label, randomized, 3-period, 3-treatment, crossover study to assess the pharmacokinetic SR (one 75-mg tramadol/650-mg acetaminophen combination tablet) formulation profiles after a single dose and IR (one 37.5-mg tramadol/325-mg acetaminophen combination tablet q6h for 2 doses) formulation profiles after 2 doses and the effect of food intake on healthy male subjects and (2) an open, randomized, 2-period, 2-treatment multiple dose crossover study to evaluate the steady-state pharmacokinetic SR and IR formulation profiles. Safety assessments were performed. Findings: Forty-three subjects completed each study protocol. The SR combination tramadol/acetaminophen formulation was clinically and statistically equivalent to the IR combination formulation in the fasting state. When tramadol and acetaminophen tablets were administered with food, the time to peak plasma concentrations and the tramadol/acetaminophen absorption were unaffected. There was no serious adverse event reported. Implications: The SR combination tramadol/acetaminophen tablet exhibited similar exposure and absorption rates compared with those of the IR formulation of tramadol, O-desmethyltramadol, and acetaminophen. The SR formulation may be more convenient for patients and has the potential to enhance compliance and pain control. ClinicalTrials.gov identifier: NCT01880125. © 2015 Elsevier HS Journals, Inc. Source


Oh E.-T.,Korea University | Jin Kim H.,Korea University | Taek Oh J.,Korea University | Su L.,Korea University | And 5 more authors.
European Journal of Organic Chemistry | Year: 2012

A practical synthesis of coenzyme Q 10 has been developed. The route features an improved Friedel-Crafts allylation of tetramethoxytoluene with a para-chlorobenzenesulfonyl-substituted C 5 allylic chloride at 40 °C. Replacement of the methyl ether protecting groups of the para-hydroquinone by methoxymethyl groups at Q 1 stage proceeded efficiently, and allowed the facile final oxidation to coenzyme Q 10 to occur under mild acidic conditions. The overall yield of coenzyme Q 10 from commercially available tetramethoxytoluene reached 53 % in this improved procedure. An improved synthesis gave CoQ 10 in 53 % overall yield from tetramethoxytoluene through Friedel-Crafts allylation with a para-chlorobenzenesulfonyl-substituted C 5 allylic chloride and a modified oxidation procedure. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source

Discover hidden collaborations